Taken together, these findings were interpreted as cutaneous marginal zone lymphoma; the patient was then referred to oncology for staging and further management. The case underscores the limitations of morphology and immunohistochemistry alone in the diagnosis of cutaneous lymphomas and demonstrates the sensitivity of flow cytometry in detecting small, abnormal lymphocyte populations that might otherwise be overlooked.
reported concurrently with other epithelial malignancies and hematologic disorders including angioimmunoblastic T-cell lymphoma, Castleman disease, and hepatocellular carcinoma. Whether iT-LBP represents a reactive process or a coincidental finding is not known. Here, we present an extraordinarily rare case of a patient who remained in the stable phase without treatment for at least 13 years.
The patient was a 54-year-old white man referred for asymptomatic lymphocytosis (6.4 K/mcL). He was 11 years post trauma splenectomy, and PMH included leukocytosis attributed to gastritis 5 years earlier at an OSH. Physical examination was unremarkable. Early technologist reviewed peripheral smears revealed "few" variant lymphocytes and smudge cells. Initial pathologist smear review, performed 10 years post-referral, noted numerous lymphoid cells with prominent cytoplasmic protrusions. The patient was initially diagnosed with post-splenectomy lymphocytosis, an impression reinforced by absent symptoms and a 5 year post-referral flow study that assessed only B-cells and was unrevealing of any clonal proliferations. A second flow study done 9 years post-referral revealed a population of CD4+/CD8+ T-cells that was also CD2, CD3, CD5, CD7, and CD52 positive. Clonal rearrangement of the TCR-gamma and deletion in the TP-53 genes were also identified. Post-referral, the ALC increased for 4 years before stabilizing at a mean of approximately 11 K/mcL. Ten years post-referral the patient developed TCC of the bladder treated with surgery and adjuvant chemotherapy. Over the next 3 years, his ALC increased to a mean of approximately 15-18 K/mcL, but 6 months prior to death acutely spiked to 85 K/mcL. Chemotherapy targeting his lymphoid neoplasm was never implemented. This case is noteworthy in that review of the English literature reveals only one case of T-PLL with longer survival time without prior therapy (18 years). Additionally, the relationship, if any, among T-cell lymphoid neoplasms, the breakdown of immune surveillance, and the occurrence of visceral neoplasm merits attention.
